Kancera AB
STO:KAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kancera AB
Other Long-Term Assets
Kancera AB
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kancera AB
STO:KAN
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other Long-Term Assets
kr22.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other Long-Term Assets
kr192m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other Long-Term Assets
kr148m
|
CAGR 3-Years
10%
|
CAGR 5-Years
71%
|
CAGR 10-Years
17%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other Long-Term Assets
kr1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
27%
|
|
|
BioArctic AB
STO:BIOA B
|
Other Long-Term Assets
kr1.5m
|
CAGR 3-Years
35%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Kancera AB
Glance View
Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. The company is headquartered in Solna, Stockholm. The company went IPO on 2011-02-21. The firm's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The firm's other activities include development of cancer models and stem cell-based techniques. The firm is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The firm's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
